P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders
B G Feagan(Western University), Irving H. Fox(Takeda (United States)), A. Parikh(Takeda (United States)), William J. Sandborn(University of San Diego), Matthew D. Smyth(University of British Columbia), Serap Sankoh(Millennium Engineering and Integration (United States))
Cited by 9
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k